Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.31 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24193268 | 0.89 | CYP2C19 (0.52) | CYP2C9CYP2C19TDP1LCKMEN1 | |
| SCHEMBL8350386 | 0.89 | CYP2C19 (0.52) | CYP2C9CYP2C19TDP1MEN1CA12 | |
| SCHEMBL4745524 | 0.89 | CYP2C9 (0.41) | CYP2C9CYP2C19TDP1LCKMEN1 | |
| SCHEMBL13863609 | 0.89 | CYP2C19 (0.52) | CYP2C9CYP2C19TDP1LCKMEN1 | |
| SCHEMBL18656421 | 0.88 | CYP2C19 (0.47) | CYP2C9CYP2C19TDP1LCKMEN1 | |
| SCHEMBL22404850 | 0.88 | CYP2C19 (0.50) | CYP2C9CYP2C19TDP1LCKMEN1 | |
| SCHEMBL26259275 | 0.88 | CYP2C19 (0.50) | CYP2C9CYP2C19TDP1LCKMEN1 | |
| SCHEMBL12598532 | 0.88 | CYP2C9 (0.40) | CYP2C9CYP2C19TDP1LCKMEN1 | |
| SCHEMBL10123924 | 0.87 | CYP2C19 (0.54) | CYP2C9CYP2C19TDP1MEN1CA12 | |
| SCHEMBL18120963 | 0.86 | CYP2C19 (0.43) | CYP2C9CYP2C19TDP1LCKMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969353-B2 | Aminoalcohol lipidoids and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-03-03 | — | — | US | disclosed |
| US-20110293703-A1 | AMINOALCOHOL LIPIDOIDS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110293703-A1 | AMINOALCOHOL LIPIDOIDS AND USES THEREOF | PHOSPHO1, PNMT, AASDHPPT | CYP2C9 1173/4885CYP2C19 1032/4885TDP1 1703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.